Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Daiichi Sankyo Ltd (OP: DSKYF ) 32.00 -1.19 (-3.59%) Streaming Delayed Price Updated: 3:49 PM EST, Nov 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Daiichi Sankyo Ltd < Previous 1 2 Next > Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients September 23, 2024 AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free... Via Benzinga AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial September 10, 2024 AstraZeneca shared detailed results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan for non-small cell lung cancer, showing a clinically meaningful trend in overall survival compared to... Via Benzinga Week In Review: Curon Out-Licenses T-Cell-Engager To Merck For $700 Million Upfront August 10, 2024 Curon Biopharmaceutical, a Shanghai company, out-licensed global rights for a clinical-stage bispecific candidate to Merck (MSD) for $700 million upfront plus $600 million in milestones. Via Talk Markets Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10 August 07, 2024 "As stock pickers, we focus on a basket of stocks that we believe will emerge from the current drawdown," strategists say. Via Benzinga Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact March 20, 2023 Via Benzinga Daiichi Sankyo Seeks Approval In Japan For Its mRNA-Based COVID-19 Vaccine January 13, 2023 Via Benzinga Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast July 30, 2024 Merck reports Q2 sales of $16.1 billion, a 7% increase YoY, beating estimates. Keytruda sales surged 16% to $7.27 billion. FDA approvals for Capvaxive and Winrevair highlight the quarter. Merck revises... Via Benzinga Exposures Product Safety FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug June 27, 2024 The FDA issued a Complete Response Letter for Daiichi Sankyo and Merck's BLA for patritumab deruxtecan targeting EGFR-mutated NSCLC due to third-party manufacturing facility inspection findings. The... Via Benzinga Exposures Product Safety 5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More June 24, 2024 Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach. Via Benzinga Why Is AstraZeneca Stock Trading Lower On Tuesday? May 28, 2024 AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance. Via Benzinga Double Good News For AstraZeneca's Breast Cancer Drugs April 29, 2024 Results from AstraZeneca's Enhertu trial vs. chemotherapy in HR-positive, HER2-low metastatic breast cancer. Via Benzinga AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor April 08, 2024 FDA approves Daiichi Sankyo's and AstraZeneca's Enhertu for unresectable or metastatic HER2+ solid tumors. Accelerated approval based on ORR and DOR. Boxed warnings for ILD/pneumonitis and embryo-fetal... Via Benzinga Exposures Product Safety What's Going On With Pfizer Stock Today? January 25, 2024 Pfizer to announce Q4 2023 earnings on 30th Jan. Analysts project EPS loss of $(0.22) and $14.25B in revenues. Via Benzinga Merck Signs Multi-Billion Deal With Japan's Daiichi Sankyo For Cancer Therapy Drug Development October 20, 2023 Merck & Company, Inc. (NYSE: MRK) and Japan's Daiichi Sankyo Co. Ltd. (OTC: DSKYF) entered into a global development and commercialization agreement. Via Benzinga Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting September 22, 2023 AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSKYF) (OTC: Via Benzinga AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials September 11, 2023 Daiichi Sankyo (OTC: DSKYF) (OTC: DSNKY) and AstraZeneca plc (NASDAQ: AZN) released initial results from the TROPION-Lung04 phase 1b tria Via Benzinga FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt July 21, 2023 The FDA has approved Daiichi Sankyo's (OTC: DSNKY) Vanflyta (quizartinib) in Via Benzinga AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial July 03, 2023 AstraZeneca Plc (NASDAQ: AZN) reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with locally advanced or metastatic non-small cell lung... Via Benzinga AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting March 06, 2023 Via Benzinga AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs December 19, 2022 Via Benzinga European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs November 14, 2022 Via Benzinga With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma September 21, 2022 Via Benzinga Seagen Suffers Loss In Arbitration Dispute Over ADC Technology August 15, 2022 Via Benzinga AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study August 15, 2022 Via Benzinga Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation August 12, 2022 Via Benzinga AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients August 09, 2022 Via Benzinga The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings July 19, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga AstraZeneca's Enhertu Wins European Approval For Pretreated Breast Cancer Setting July 19, 2022 Via Benzinga The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies June 27, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga EMA's Advisory Committee Backs Approval For AstraZeneca's Targeted Breast Cancer Therapies June 27, 2022 Via Benzinga < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
